ProCE Banner Activity

My Take on Viral Hepatitis Treatment Advances From AASLD 2022: US Perspective

Conference Coverage
Clinical Thought

One of the biggest messages from AASLD 2022 was that we still have a lot of work to do. Between the pandemic and propagation of unhealthy behaviors, there’s still an incredible burden of liver disease, and viral hepatitis continues to contribute to it.

Released: December 02, 2022

Share

Faculty

Nancy Reau

Nancy Reau, MD

Professor of Medicine
Richard B. Capps Chair of Hepatology
Chief, Section of Hepatology
Associate Director, Solid Organ Transplantation
Rush University Medical Center 
Chicago, Illinois

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

Gilead Sciences, Inc.

Faculty Disclosure

Primary Author

Nancy Reau, MD

Professor of Medicine
Richard B. Capps Chair of Hepatology
Chief, Section of Hepatology
Associate Director, Solid Organ Transplantation
Rush University Medical Center 
Chicago, Illinois

Nancy Reau, MD: consultant/advisor/speaker: AbbVie, Arbutus, Gilead, Salix.